LL-37 (Cathelicidin): What Lakeland Readers Should Know

LL-37 is a germ-fighting peptide your body makes in the skin and other tissues. It has been tested as a wound treatment, and some clinics and online sellers offer it for other uses. This page explains what the research found and where its status stood in November 2026. It is general information, not advice for your situation.

What it is and how it works

LL-37 is a chain of 37 amino acids cut from a larger human protein called cathelicidin (hCAP18). It is part of the body’s built-in, or innate, defense against germs. Researchers found plenty of LL-37 in fresh wounds but little in chronic wounds. That led a drug company to develop it as a topical wound treatment under the name ropocamptide.¹

LL-37 cuts both ways. People with rosacea have abnormally high, abnormally processed cathelicidin in their facial skin, and those forms increased skin inflammation in mice.² In psoriasis, LL-37 bound to the body’s own DNA can set off an immune alarm signal.³ So claims that “boosting” LL-37 is good for skin deserve caution.

What the research shows (and where evidence is weak)

• Venous leg ulcers, first trial. In a 34-person randomized trial (people assigned by chance to LL-37 or placebo, a dummy treatment), only the lowest concentration was linked to faster healing-rate measures in a 4-week trial. The highest strength did no better than placebo.⁴
• Venous leg ulcers, larger trial. A 148-patient phase IIb trial (a mid-stage test of whether a drug works) ran for 13 weeks. It found no significant improvement over placebo in the full group. A benefit showed up only when researchers looked back at a subgroup with large wounds, which is not reliable proof. The developer ran the trial, and company employees were authors.¹
• Diabetic foot ulcers. One small trial in Indonesia reported more healthy new wound tissue with LL-37 cream over 4 weeks. That is a short-term marker, not full healing, and the cream did not reduce bacteria on the wound.⁵
• Injections. No human trials of injected LL-37 were found in the research behind this page.

FDA and regulatory status

Not an approved drug. LL-37 is not FDA-approved. FDA has reviewed it only as a possible ingredient for pharmacy compounding.⁶

FDA’s safety-concern list. FDA had placed LL-37 on its “Category 2” list of bulk ingredients that may pose significant safety risks in compounding. FDA said it “lacks sufficient safety-related information” to know whether LL-37 would harm people. It added that animal research suggests harm to male reproduction and that LL-37 “can be protumorigenic in some tissues,” meaning it may promote tumor growth. By April 22, 2026, the nominations were withdrawn; FDA still lists its safety concerns.⁶

Upcoming review. According to a law-firm summary, FDA’s compounding advisory committee plans to consider LL-37 at a meeting before the end of February 2027.⁷ As of November 13, 2026, we did not find a meeting date or outcome for that review. Check FDA’s advisory committee calendar for updates.

2026 HHS draft policy. According to law-firm summaries, LL-37 is not among the six peptides in HHS’s October 2026 draft compounding enforcement policy.⁸

Sport. LL-37 is not named on WADA’s 2026 Prohibited List.⁹ It is likely covered by WADA’s ban on unapproved substances; athletes should check with their anti-doping organization.

Common side effects and safety

• Topical use on ulcers was well tolerated in the trials. In the larger trial there were no deaths. Twelve serious events occurred in 11 patients, and none were judged to be caused by LL-37.¹
• Injected use has not been studied in people. The trial safety data say nothing about injections.
• FDA’s concerns include possible harm to male reproduction and possible tumor promotion in animal research, plus possible immune reactions and impurities in compounded products.⁶

Products sold online as “research peptides” are not made or checked as medicines. See our guide to research chemical peptide risks.

Typical cost range

There is no reliable price data. LL-37 is not an approved product, so there is no official list price, and no published cost analysis was found. Prices vary between clinics and pharmacies. Ask any provider for a written price breakdown before you start.

Questions to ask a provider

• What evidence supports LL-37 for my problem, given that the larger wound trial was negative?
• Where does your product come from, and which state-licensed pharmacy makes it?
• How do FDA’s concerns about male reproduction and tumor growth apply to me?
• Do I have rosacea, psoriasis or another condition where LL-37 might make things worse?
• What better-studied options should I try first?
• What is the total cost?

See also our guide to how to vet a peptide clinic.